MX2017013154A - Conjugados anticuerpo-farmaco de sitio especifico. - Google Patents
Conjugados anticuerpo-farmaco de sitio especifico.Info
- Publication number
- MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A
- Authority
- MX
- Mexico
- Prior art keywords
- site
- specific antibody
- drug conjugates
- amino acid
- antibody
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506393.6A GB201506393D0 (en) | 2015-04-15 | 2015-04-15 | Site-specific antibody-drug conjugates |
| PCT/EP2016/058371 WO2016166299A1 (en) | 2015-04-15 | 2016-04-15 | Site-specific antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013154A true MX2017013154A (es) | 2018-02-21 |
Family
ID=53333825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013154A MX2017013154A (es) | 2015-04-15 | 2016-04-15 | Conjugados anticuerpo-farmaco de sitio especifico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180125994A1 (enExample) |
| EP (1) | EP3283118A1 (enExample) |
| JP (1) | JP2018511628A (enExample) |
| KR (1) | KR20170137115A (enExample) |
| CN (1) | CN107683146A (enExample) |
| AU (1) | AU2016249877A1 (enExample) |
| BR (1) | BR112017022256A2 (enExample) |
| CA (1) | CA2981920A1 (enExample) |
| GB (1) | GB201506393D0 (enExample) |
| MX (1) | MX2017013154A (enExample) |
| WO (1) | WO2016166299A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6704532B1 (ja) | 2017-02-08 | 2020-06-03 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| SI3544636T1 (sl) | 2017-02-08 | 2021-08-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| HRP20221063T1 (hr) | 2017-04-18 | 2022-11-11 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| US11596696B2 (en) | 2017-04-20 | 2023-03-07 | Adc Therapeutics Sa | Combination therapy with an anti-CD25 antibody-drug conjugate |
| EP3612235A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy with an anti-psma antibody-drug conjugate |
| US11426467B2 (en) | 2017-06-14 | 2022-08-30 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD25 ADC |
| JP7220203B2 (ja) | 2017-08-18 | 2023-02-09 | メドイミューン・リミテッド | ピロロベンゾジアゼピン複合体 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| US20220347309A1 (en) | 2018-12-19 | 2022-11-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| JP7210770B2 (ja) * | 2019-03-29 | 2023-01-23 | メドイミューン・リミテッド | 化合物及びその複合体 |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| KR20240049342A (ko) * | 2021-08-27 | 2024-04-16 | 얀센 바이오테크 인코포레이티드 | 항-psma 항체 및 이의 용도 |
| CN116370651A (zh) * | 2023-04-04 | 2023-07-04 | 上海愿智生物技术有限公司 | 一种抗psma抗体-药物缀合物及其制备方法和应用 |
| WO2025145034A1 (en) * | 2023-12-29 | 2025-07-03 | T.O.A.D. Oncology Sa | Anti-psma conjugates and methods of using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| WO2006065533A2 (en) * | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| WO2011108714A1 (ja) * | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2638066A4 (en) * | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| PT2906253T (pt) * | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| ES2680153T3 (es) * | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| MX2016002545A (es) * | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso. |
-
2015
- 2015-04-15 GB GBGB1506393.6A patent/GB201506393D0/en not_active Ceased
-
2016
- 2016-04-15 AU AU2016249877A patent/AU2016249877A1/en not_active Abandoned
- 2016-04-15 CA CA2981920A patent/CA2981920A1/en not_active Abandoned
- 2016-04-15 CN CN201680022066.8A patent/CN107683146A/zh active Pending
- 2016-04-15 US US15/566,411 patent/US20180125994A1/en not_active Abandoned
- 2016-04-15 KR KR1020177030351A patent/KR20170137115A/ko not_active Withdrawn
- 2016-04-15 JP JP2017553879A patent/JP2018511628A/ja active Pending
- 2016-04-15 WO PCT/EP2016/058371 patent/WO2016166299A1/en not_active Ceased
- 2016-04-15 BR BR112017022256A patent/BR112017022256A2/pt not_active Application Discontinuation
- 2016-04-15 EP EP16716583.6A patent/EP3283118A1/en not_active Withdrawn
- 2016-04-15 MX MX2017013154A patent/MX2017013154A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017022256A2 (pt) | 2018-07-31 |
| JP2018511628A (ja) | 2018-04-26 |
| EP3283118A1 (en) | 2018-02-21 |
| CN107683146A (zh) | 2018-02-09 |
| GB201506393D0 (en) | 2015-05-27 |
| WO2016166299A1 (en) | 2016-10-20 |
| KR20170137115A (ko) | 2017-12-12 |
| CA2981920A1 (en) | 2016-10-20 |
| US20180125994A1 (en) | 2018-05-10 |
| AU2016249877A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013154A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| ZA201706745B (en) | Site-specific antibody-drug conjugates | |
| MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| ZA201805336B (en) | Amanitin conjugates | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
| ZA201903062B (en) | Amanitin antibody conjugates | |
| BR112016004242A2 (pt) | métodos para conjugação sítio-específica de anticorpos e composições | |
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
| PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| MX395142B (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| IN2015DN02577A (enExample) | ||
| WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
| ZA202001747B (en) | Psma-targeting amanitin conjugates | |
| WO2015164392A3 (en) | Novel antii-rnf43 antibodies and methods of use | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| MA39909A (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
| WO2018053552A3 (en) | Isoquinolidinobenzodiazepines | |
| WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| IL272931A (en) | Peptide conjugates, conjugation process and their uses | |
| EP3775186A4 (en) | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND THEIR USES |